Imvanex (Modified Vaccinia Ankara – Bavarian Nordic Live Virus)

The Modified Vaccinia Ankara (MVA) virus in Imvanex is replication‑deficient and carries orthopoxvirus antigens. After subcutaneous injection, it is processed by antigen‑presenting cells, stimulating both antibody production and cellular T‑cell responses that together confer long‑lasting protection against smallpox and monkeypox.

The dose and schedule of Imvanex are determined by the prescribing clinician based on the patient’s age, health status, and indication. Healthcare providers follow official guidelines and product labeling to ensure appropriate administration.

Safety data for Imvanex in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Imvanex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imvanex uses the Modified Vaccinia Ankara strain, which is replication‑deficient and generally has a better safety profile than traditional replicating vaccinia vaccines. It is especially suitable for immunocompromised individuals, whereas older vaccines may carry higher risks of adverse events.

Imvanex must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain management is essential to maintain vaccine potency.

Imvanex is given as a subcutaneous injection using a sterile needle and syringe. The injection is typically performed by a trained healthcare professional in a clinical setting, following aseptic technique and standard vaccination protocols.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, extensive skin eruptions, neurological complications like encephalitis, cardiac inflammation (myocarditis), and blood disorders such as thrombocytopenia. Immediate medical attention is required if any of these occur.

Imvanex is contraindicated in individuals with severe immunodeficiency, uncontrolled HIV infection, those receiving high‑dose immunosuppressive therapy, and persons with a known severe allergy to any component of the vaccine. Pregnant or breastfeeding women should only receive it when clearly indicated.